AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The Illinois-based company ABBV, which is the parent of drug brands Botox and Skyrizi, echoed recent comments from fellow drugmaker Johnson & Johnson JNJ. AbbVie also brought up issues it had with ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

In 2025, health means staying alive from the inside. Taking advantage of the bedeviled blessing of insurance, scheduling ...